Payment overview · 2025
General Payments
$2,894.64
140 reported records · 26 companies
Healthcare provider profile · identity verified
Sunil Kumar Sharma, MD
Allopathic & Osteopathic Physicians|Family Medicine · OPELIKA, AL · NPI 1376604272
Verified facts
What the public records show
CMS Open Payments records show Sunil Kumar Sharma, MD received $2,894.64 in general payments during 2025 across 140 reported records.
PFIZER INC. accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Fanapt, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 273 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $524.76 | 18.1% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $375.35 | 13.0% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $206.00 | 7.1% | 11 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$204.70 | 7.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $164.40 | 5.7% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $152.00 | 5.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.49 | 5.2% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $137.09 | 4.7% | 11 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $114.89 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $112.79 | 3.9% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $87.03 | 3.0% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $83.87 | 2.9% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $82.47 | 2.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.48 | 2.8% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $79.75 | 2.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $63.36 | 2.2% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $53.04 | 1.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.52 | 1.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.25 | 1.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.68 | 1.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.15 | 0.9% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $23.60 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.73 | 0.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.64 | 0.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.43 | 0.5% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $14.17 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,894.64 | 140 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $482.40 | 20 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $204.70 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $190.22 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $168.15 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $167.49 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $164.40 | 13 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $152.00 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $149.49 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $126.96 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $124.78 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.58 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $114.89 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $104.44 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.34 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $87.03 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $83.87 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $82.47 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.48 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $80.48 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.36 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $53.04 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.52 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $41.71 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.51 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.65 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.65 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.94 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 273 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 119 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 163 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 225 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 193 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 121 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
121 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
119 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
119 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
121 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
225 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
193 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
273 | 49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1035 | 281 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1024 | 203 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1007 | 283 |
| Amlodipine Besylate | Amlodipine Besylate | 846 | 230 |
| Pantoprazole Sodium | Pantoprazole Sodium | 758 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 688 | 185 |
| Tramadol Hcl | Tramadol Hcl | 639 | 140 |
| Clonazepam | Clonazepam | 555 | 120 |
| Alprazolam | Alprazolam | 545 | 123 |
| Losartan Potassium | Losartan Potassium | 504 | 168 |
| Omeprazole | Omeprazole | 483 | 123 |
| Famotidine | Famotidine | 478 | 122 |
| Lisinopril | Lisinopril | 466 | 134 |
| Metoprolol Succinate | Metoprolol Succinate | 398 | 106 |
| Potassium Chloride | Potassium Chloride | 378 | 105 |
| Meloxicam | Meloxicam | 366 | 96 |
| Furosemide | Furosemide | 353 | 80 |
| Carvedilol | Carvedilol | 350 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 337 | 126 |
| Zolpidem Tartrate | Zolpidem Tartrate | 337 | 66 |
| Metformin Hcl | Metformin Hcl | 335 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 327 | 79 |
| Montelukast Sodium | Montelukast Sodium | 319 | 92 |
| Trazodone Hcl | Trazodone Hcl | 308 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 289 | 89 |
| Eliquis | Apixaban | 273 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 266 | 91 |
| Duloxetine Hcl | Duloxetine Hcl | 237 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 234 | 78 |
| Simvastatin | Simvastatin | 227 | 70 |
| Mounjaro | Tirzepatide | 225 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 217 | 73 |
| Metformin Hcl Er | Metformin Hcl | 208 | 62 |
| Pregabalin | Pregabalin | 207 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 63 |
| Ozempic | Semaglutide | 193 | 45 |
| Sertraline Hcl | Sertraline Hcl | 192 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 58 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 189 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 183 | 33 |
| Lorazepam | Lorazepam | 181 | 39 |
| Donepezil Hcl | Donepezil Hcl | 179 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 56 |
| Bupropion Xl | Bupropion Hcl | 178 | 33 |
| Memantine Hcl | Memantine Hcl | 178 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 166 | 37 |
| Jardiance | Empagliflozin | 163 | 31 |
| Ezetimibe | Ezetimibe | 161 | 60 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 155 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 155 | 29 |
| Buspirone Hcl | Buspirone Hcl | 153 | 39 |
| Allopurinol | Allopurinol | 152 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 149 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 59 |
| Sucralfate | Sucralfate | 142 | 38 |
| Glimepiride | Glimepiride | 139 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 38 |
| Celecoxib | Celecoxib | 130 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 129 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 126 | 31 |
| Linzess | Linaclotide | 121 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 28 |
| Farxiga | Dapagliflozin Propanediol | 119 | 30 |
| Myrbetriq | Mirabegron | 119 | 26 |
| Mirtazapine | Mirtazapine | 110 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 107 | 20 |
| Januvia | Sitagliptin Phosphate | 106 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 103 | 26 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 102 | 16 |
| Diazepam | Diazepam | 100 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 99 | 78 |
| Xarelto | Rivaroxaban | 99 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 32 |
| Spironolactone | Spironolactone | 95 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 24 |
| Atenolol | Atenolol | 87 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 29 |
| Ondansetron Odt | Ondansetron | 87 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 22 |
| Clonidine Hcl | Clonidine Hcl | 82 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 26 |
| Rivastigmine | Rivastigmine Tartrate | 76 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 19 |
| Propranolol Hcl | Propranolol Hcl | 73 | 17 |
| Azithromycin | Azithromycin | 71 | 56 |
| Levetiracetam | Levetiracetam | 69 | 17 |
| Enalapril Maleate | Enalapril Maleate | 66 | 22 |
| Synthroid | Levothyroxine Sodium | 63 | 13 |
| Baclofen | Baclofen | 62 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 25 |
| Lamotrigine | Lamotrigine | 61 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | suppressed |
| Risperidone | Risperidone | 59 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 16 |
| Amoxicillin | Amoxicillin | 56 | 42 |
| Fluconazole | Fluconazole | 56 | 41 |
| Vascepa | Icosapent Ethyl | 56 | 12 |
| Divalproex Sodium | Divalproex Sodium | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 17 |
| Lansoprazole | Lansoprazole | 55 | 12 |
| Silodosin | Silodosin | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 28 |
| Methylprednisolone | Methylprednisolone | 53 | 39 |
| Topiramate | Topiramate | 52 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 18 |
| Estradiol | Estradiol | 50 | 14 |
| Methocarbamol | Methocarbamol | 49 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 49 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 48 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 16 |
| Acyclovir | Acyclovir | 45 | 14 |
| Meclizine Hcl | Meclizine Hcl | 45 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | 11 |
| Fenofibrate | Fenofibrate | 44 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 44 | 13 |
| Latanoprost | Latanoprost | 43 | suppressed |
| Olanzapine | Olanzapine | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 18 |
| Mupirocin | Mupirocin | 42 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 32 |
| Tradjenta | Linagliptin | 42 | suppressed |
| Valsartan | Valsartan | 42 | 19 |
| Benazepril Hcl | Benazepril Hcl | 41 | 17 |
| Colchicine | Colchicine | 41 | 19 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 41 | 21 |
| Bumetanide | Bumetanide | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 40 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Prednisone | Prednisone | 37 | 12 |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 16 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 35 | 11 |
| Cephalexin | Cephalexin | 35 | 32 |
| Icosapent Ethyl | Icosapent Ethyl | 35 | 14 |
| Levofloxacin | Levofloxacin | 35 | 24 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 34 |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | 11 |
| Ramipril | Ramipril | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 17 |
| Glipizide | Glipizide | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 11 |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Progesterone | Progesterone, Micronized | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | 11 |
| Temazepam | Temazepam | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 22 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 29 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | 11 |
| Lactulose | Lactulose | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Torsemide | Torsemide | 26 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 25 | suppressed |
| Nystatin | Nystatin | 25 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Fanapt | Iloperidone | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Trulance | Plecanatide | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 21 |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 12 |
| Rybelsus | Semaglutide | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,894.64 · 140 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dyanavel XR, ELIQUIS, ENTRESTO, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, Fabhalta, IBSRELA, INSPIRE, JARDIANCE, Kerendia, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, REXULTI, TRELEGY ELLIPTA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error